.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DE03_Cefozopran.Cefozopran

Information

Cefozopran is a fourth-generation cephalosporin antibiotic used primarily in Japan for the treatment of a broad spectrum of bacterial infections, including respiratory tract, urinary tract, skin, and intra-abdominal infections. It is administered mainly in hospital settings and is not currently approved in the US or EU.

Pharmacokinetics

Healthy adult subjects after single intravenous administration.

References

1. Wu, GL, et al., & Wu, LH (2015). Pharmacokinetics of cefozopran by single and multiple intravenous infusions in healthy Chinese volunteers. Drugs in R&D 15(1) 63–70. DOI:10.1007/s40268-014-0075-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25644122

2. Nomura, K, et al., & Taniwaki, M (2008). Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis. The Journal of antimicrobial chemotherapy 61(4) 892–900. DOI:10.1093/jac/dkn038 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18276604

3. Ikawa, K, et al., & Kobayashi, R (2009). Population pharmacokinetic modeling and pharmacodynamic assessment of cefozopran in pediatric patients. The Japanese journal of antibiotics 62(5) 435–444. PUBMED:https://pubmed.ncbi.nlm.nih.gov/20055120

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)